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Objectives: Assess the prevalence of comorbidities among PsO patients with PsA 
(PsO+PsA) and without PsA (PsO-alone) treated with biologics in UK/Germany/
France/Italy/Spain (5EU). MethOds: A multi-country multi-center medical chart-
review study of PsO patients was conducted in 4Q2012 among physician (mainly-
dermatologists) in hospitals and private practices to collect de-identified data on 
patients who were recently treated with a biologic as part of usual care. Physicians 
were screened for duration of practice (3-30 yrs) and patient volume (incl. > 2 PsO 
biologic patients/month) and recruited from a large panel to be geographically rep-
resentative in each country. Physicians abstracted charts of next five consecutive 
patients within each center/practice, and collected patient diagnosis/symptomatol-
ogy, disease-severity (physician-judgment), comorbidities and treatment patterns/
dynamics. Prevalence of comorbidities among PsO+PsA and PsO-alone patients 
was evaluated. Results: 1064 eligible Psoriasis patients were included in the 
analysis (UK:19%, Germany:21%, France:21%, Italy:18%, SP:22%). Prevalence of PsA 
among PsO patients was: 13% (UK:13%, Germany:16%, France:15%, Italy:9%, SP:13%), 
thereby defining PsO+PsA(13%) and PsO-alone(87%) cohort size. Patient character-
istics differed between patient groups (All/PsO+PsA/PsO-alone)- age:48/49/47yrs; 
female:38%/46%.37%; in-remission:42%/48%/41%; mild-disease-severity:23%-
each; moderate-disease-severity:23%/18%/23%; severe-disease:13%/11%/13%; UK 
(20%) and Germany (30%) had disproportionately more severe patients within 
PsO+PsA and PsO-alone groups respectively. Comorbidities (> = 1) were observed 
in 55% of patients (UK:55%, Germany:52%, France:63%, Italy:44%, SP:59%); top-10 
comorbidities observed were (All/PsO+PsA/PsO-alone): obesity(20%/27%/19%), 
dyslipidemia(19%/21%/19%), diabetes(12%/19%/11%), anxiety(8%/10%/8%), heart 
disease(7%/6%/7%), depression(6%-per-group), liver disease(4%/8%/3%), migraine/
headache(2%/4%/2%), asthma(2%/3%/2%), osteoarthritis(2%/2%/1%). Skin cancer, 
IBD, ankylosing spondylitis and other respiratory conditions were ~1% each per 
group. Key comorbidity outliers were (country:All/PsO+PsA/PsO-alone): dyslipidemia 
(Spain:28%/40%/27%), obesity (Spain:24%/43%/21%), diabetes (France:16%/21%/15%), 
anxiety (France:17%/24%/15%), heart disease (Germany:15%/14%/15%), liver-disease 
(Spain:7%/17%/5%). cOnclusiOns: Burden of comorbidities among Psoriasis 
patients is high, and significantly more so among subset of patients with PsA. This 
burden varied within 5EU. A multi-faceted approach to patient management is war-
ranted to manage these patients optimally and alleviate disease burden.
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Objectives: The PALACE 1 study compared the efficacy and safety of apremilast 
(APR) with placebo in patients with active psoriatic arthritis despite prior conven-
tional disease-modifying antirheumatic drugs (DMARDs) and/or biologics. The 
objective of the study was to assess the impact of APR therapy on physical func-
tioning in patients enrolled in the PALACE 1 study. MethOds: Patients were rand-
omized 1:1:1 to placebo, APR 20 mg BID (APR20), or APR 30 mg BID (APR30) stratified 
by baseline DMARD use (yes/no). Treatment efficacy was assessed at Week 16 based 
on the full analysis set population. Physical function, a pre-specified secondary 
end point, was measured in patients using the 36-item Short-Form Health Survey 
version 2 (SF-36v2) Physical Function (PF) domain, SF-36v2 physical component 
summary (PCS), and Health Assessment Questionnaire-Disability Index (HAQ-DI) 
scores. Results: 504 patients were randomized (49.4%: male; mean age: 50.4 years). 
At Week 16, the physical function change from baseline was significantly improved 
with APR30 vs. placebo, as measured by the SF-36v2 PF (4.23 vs. 1.81; P= 0.006), 
SF-36v2 PCS (4.59 vs. 2.39; P= 0.0097), and HAQ-DI (-0.244 vs. -0.086; P= 0.0017) scores. 
APR20 was associated with a significant improvement in the HAQ-DI score (-0.198 
vs. -0.086; P= 0.025), but not in the SF-36v2 PF (3.5 vs. 1.81; P= 0.050) and SF-36v2 PCS 
(3.53 vs. 2.39; P= 0.175) scores at Week 16. cOnclusiOns: While both APR30 and 
APR20 showed a benefit in disability over 16 weeks, APR30 is consistently effective 
as measured by the improvement compared with placebo in the SF-36v2 PF, SF-36v2 
PCS, and HAQ-DI scores in patients with active psoriatic arthritis.
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Objectives: To compare ACR responses between novel DMARDs, either as mono-
therapy or in combination with methotrexate (MTX), including subcutaneous (SC) 
abatacept and SC tocilizumab (TCZ), in RA patients with an inadequate response 
to conventional DMARDs (DMARD-IR). MethOds: A systematic literature review 
identified 30 randomized clinical trials (RCTs) that evaluated abatacept (intravenous 
[IV] and SC), anakinra, adalimumab, certolizumab pegol, etanercept, golimumab, inf-
liximab, tofacitinib, and TCZ (IV and SC). Reported treatment effects--ACR responses 
at 24 weeks--were synthesized by means of Bayesian network meta-analyses to 
compare the different treatments as monotherapy and combination therapy. The 
effects of anti-tumor necrosis factor (aTNF) therapy were assumed to be inter-
changeable. aTNF data were pooled. Results: The combination therapies aTNFs 
+ MTX, tofacitinib + MTX, abatacept IV/SC + MTX, and TCZ IV/SC + MTX dem-
onstrated comparable ACR responses while anakinra + MTX was less efficacious. 
Objectives: Evaluate treatment patterns, health care utilization and costs of 
chronic hepatitis C (CHC) patients receiving direct-acting antiviral (DAA) protease 
inhibitors. MethOds: Adult patients with ≥ 1 claim for CHC (ICD-9-CM codes 070.44, 
070.54, 070.70, 070.71) and a fill of boceprevir or telaprevir were selected from a 
de-identified US-based claims database (2006-2012). The date of the first fill for a 
DAA after 5/13/2011 (date of first DAA availability) was defined as the index date; 
patients were categorized into either the telaprevir or boceprevir cohorts. Patients 
had continuous eligibility and no claims for hepatitis B during the 6-months before 
(baseline) and 12-months following (study period) the index date. Baseline charac-
teristics and study period treatment patterns, health care utilization and costs were 
described. Adjusted study period costs were compared between the DAA cohorts 
using multivariate analyses. Results: There were 871 telaprevir and 284 boceprevir 
patients identified. DAA patients were 54 years old on average and more often male 
(62%). Approximately 25% of telaprevir and 18% of boceprevir patients had cirrhosis, 
and 9% of telaprevir and 7% of boceprevir patients had decompensated cirrhosis 
at baseline. Less than 1% of patients were HIV co-infected. Approximately 54% 
of telaprevir and 74% of boceprevir patients did not complete minimum recom-
mended therapy (telaprevir: 12 weeks of triple+12 weeks of dual, boceprevir: 4±1 
weeks of lead-in+24 weeks of triple). During the study period, over half of patients 
had anemia (boceprevir: 55%, telaprevir: 54%). Study period health care utilization 
measures were generally similar between the DAA cohorts. Telaprevir patients expe-
rienced numerically higher study period unadjusted medical (boceprevir: $16,927, 
telaprevir: $19,519) and drug costs (boceprevir: $59,953, telaprevir: $76,497) than 
boceprevir patients; however, after adjusting for baseline characteristics, only drug 
costs remained significantly different. cOnclusiOns: CHC patients receiving 
telaprevir or boceprevir experienced high rates of early discontinuation and high 
medical and drug costs.
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Objectives: This study aims to explore medical care costs between cases with/
without hospital-acquired falls using prospective payment system data accord-
ing to ICD10. MethOds: We had 23,336 in-patients with more than 16 years old 
between April, 2010 and March, 2012 at St. Mary’s Hospital in Kurume, Japan. There 
were 387 injured cases for falls. We examined length of hospital stay (LOS), Falls rate 
and medical care cost including medication and injection fee during hospitaliza-
tion. Results: We classified two groups, 387 injured cases with falls and 22,949 
cases without falls. The average age (mean ± standard deviation) were 72.0 ± 14.2 
years old for cases with falls and 59.7 ±20.3 y.o. for cases without falls. The LOS 
were 68.3 ±95.4 days and 18.9 ± 28.4 days. According to ICD10, LOS for Mental and 
Behavioral Disorders (F00-F99) was the longest (61.6 days) and Falls rate was the 
highest (90.9 1000pt･days). LOS for Factors influencing health status and contact 
with health services (Z00-Z99) among ICD10 codes and Falls Rate was the lowest 
(0 1000pt･days) among ICD10 codes. We assessed the highly positive association 
between length of hospital stay and Falls rate (y = 0.0016x - 0.013, R² = 0.8601). Total 
medical care cost were 26,971 USD for injured cases with falls and 9,937 USD for 
cases without falls, medication fee were 565 USD cases with falls and 162 USD for 
cases without falls, and injection fee were 2002 USD for injured cases with falls and 
670 USD for cases without falls. cOnclusiOns: We realized the length of hospital 
stay is longer, Falls rate is higher and total medical care cost, medication fee, and 
injection fee are higher. In order to prevent hospital-acquired falls, we have to 
make assessments for falls and take an appropriate measure from the viewpoint 
of ICD10 codes.
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Objectives: A technical nerve injury is a new or worsening nerve injury follow-
ing spine surgery. These injuries can be sub-categorized into cord injuries (new or 
worsening injury of the spinal cord or cauda equina injury), and radiculopathies 
(new or worsening sensory or motor deficit that follows the distribution of a specific 
nerve root). The goal of this study was to assess the risk factors that predict technical 
nerve injury from spine surgery. MethOds: The Spine End Results Registry (SERR) 
is a prospective data registry of all patients (N= 1745) who underwent spine surgery 
from 1/1/2003 to 12/31/2004, at two academic hospitals. We modeled the predictive 
probability of various medical risk factors contributing to a technical nerve injury 
using a logistic random intercept model. The model was adjusted for diagnosis 
group, comorbidities, surgical invasiveness, age and gender, with a random inter-
cept term (surgeon), accounting for correlation, and a random slope (surgeon year 
of experience). A shrinkage estimator was used to predict the random effect of a 
surgeon. Surgical invasiveness is a score summed for the number of vertebral levels 
decompressed, arthrodesed, or instrumented, and surgical approach. Results: The 
adjusted multivariate regression analyses, the odds of a patient experiencing a tech-
nical injury was 0.008 (95% CI: 0.001, 0.042). The odds of a technical injury is < 1% for 
the average patient. No medical risk factors were significantly associated with the 
probability of experiencing a technical injury during surgery. The odds of a technical 
injury increased by 6% within a patient for each unit difference in surgical invasive-
ness (OR= 1.06, 95% CI: 1.03, 1.09, p < 0.001). cOnclusiOns: There was insufficient 
evidence from the data to suggest that medical risk factors are associated with the 
probability of a technical injury. The highest probability of experiencing a technical 
injury following spine surgery is having a more invasive surgery.
